Sandoz says new clinical data support two biosimilars
ZURICH (Reuters) – Novartis’ generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.
Adalimumab is a copy of AbbVie’s Humira, while rituximab copies MabThera/Rituxan by Roche and Biogen.
The trials showed the efficacy and safety of biosimilar adalimumab and the safety of biosimilar rituximab matched their reference medicines in studies of multiple-switching and retreatment, Sandoz said on Tuesday.
Biosimilar adalimumab is under European regulatory review, while biosimilar rituximab has already been approved in Europe and is under review by the U.S. Food and Drug Administration.
For more details see:
Reporting by Michael Shields, editing by Louise Heavens
#USA #News #USnews #worldnews #headlinenews #Breakingnews #weathernews #UnitedStates news #CanadianNews #weatherforecast top news #stories, #hourlyweather #Reuters
Fire breaks out at Cambridge industrial building
CTV Kitchener Published Monday, November 20, 2017 2:33PM EST Last Updated Monday, November 20, 2017Read More
Babies learn what words mean before they can use them
(Reuters Health) – Babies begin to learn words and what they mean well before theyRead More